RE:RE:RE:RE:RE:RE:RE:RE:Pfizer Pfizer Unveils Priorities for Its New Oncology Organization
This new Pfizer initiative will be fueled partly by steady growth in cancer prevalence and incidence. ‘We have a clear strategy focused on three core scientific modalities and four main types of cancer, where we have the deep expertise and knowledge to advance our leadership. With many significant catalysts expected through the first half of 2025 and beyond, our Oncology organization is well-positioned to be a critical driver of potential long-term sustainable sales and profit growth for Pfizer through the end of the decade,” said Boshoff. The three core modalities are: small molecules, ADCs, and bispecific antibodies, including other immuno-oncology biologics. In particular, Pfizer is progressing a next-generation ADC platform aimed at novel targets and improved, differentiated payloads, as well as investigational advanced biologics and novel combinations of medicines.
https://www.insideprecisionmedicine.com/topics/oncology/pfizer-unveils-priorities-for-its-new-oncology-organization/
The ADC + ICI combination is now being explored specifically in patients with HER2+ and PD-L1+ metastatic breast cancer, however there are those MBC patients who have unresponsive PD-L1 (negative) tumors, particular to immunosuppressive tumor microenvironments (TME), which are unresponsive to PD-L1 immune checkpoint inhibitors.
Consequently in PD-L1- (negative) patients, the addition of ONCY's pelareorep in advance of of an immune checkpoint inhibitor would turn a PD-L1- (negative) "cold" tumor into a PD-L1+ "hot" tumor, while remodeling an otherwise immunosuppressive TME and increasing the level of effector T-cells (TiLs) , resulting in a receptive TME that will respond positively to antibody drug conjugate (ADC) + PD-L1 immune checkpoint inhibitor therapy, and ultimately overcome T cell resistance and T cell exhaustion, that is normally experienced with ADCs and ICI therapies in cancer cell TME's with low TiL levels.